Would you consider measuring anti–factor Xa activity to monitor low-molecular-weight heparin in patients with catastrophic antiphospholipid syndrome (CASP)/ paraneoplastic thrombosis +/- obesity ?
LMWH is highly reliable, and anti Xa activity not so easy to measure - if clinical evolution is good , I'll just use usual therapeutic doses (1mg/k 12-12h sc) - if any thing very out of expected maybe try to measure